NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Thursday 11 May 2023

**Location:** Hybrid meeting - Via Zoom and NICE Manchester office

## Attendees

Committee members present

1. Dr Stephen Smith (Chair) Present for all items
2. Martin Bradley Present for all items
3. Dr Matthew Bradley Present for all items
4. Elliott Dash Present for all items
5. Professor Sofia Dias Present for all items
6. Professor Rachel Elliott Present for all items
7. Andrew Fox Present for all items
8. Dr Andrew Hitchings Present for all items
9. Dr Robert Hodgson Present for all items
10. Dr Bernard Khoo Present for all items
11. Dr Ivan Koychev Items 1 to 3.2.2
12. Dr Guy Makin Present for all items
13. Dr Philip Mallender Present for all items
14. Professor David Meads Present for all items
15. Giles Monnickendam Present for all items
16. Dr Nathan Moore Present for all items
17. Dr Malcolm Oswald Present for all items
18. Professor Chris Parker Items 1 to 3.2.2
19. Dr Rebecca Payne Present for all items
20. Carole Pitkeathley Present for all items
21. Dr Raju Reddy Present for all items
22. Professor John Watkins Present for all items

NICE staff (key players) present

Linda Landells, Associate Director Items 1 to 3.2.2

Jasdeep Hayre, Associate Director Items 4 to 4.2.2

Celia Mayers, Project Manager Present for all items

Lizzie Walker, Heath Technology Assessment Adviser Items 1 to 3.2.2

Caron Jones, Heath Technology Assessment Adviser Items 4 to 4.2.2

Owen Swales, Heath Technology Assessment Analyst Items 1 to 3.2.2

Alice Pritchard, Heath Technology Assessment Analyst Items 1 to 3.2.2

Rachel Ramsden, Heath Technology Assessment Analyst Items 4 to 4.2.2

External assessment group representatives present

Jo Lord, Southampton Health Technology Assessment Centre (SHTAC), Items 1 to 3.1.3

Geoff Frampton, Southampton Health Technology Assessment Centre (SHTAC), Items 1 to 3.1.3

Paul Tappenden, School of Health and Related Research (ScHARR), Items 4 to 4.1.3

Aline Navega-Biz, School of Health and Related Research (ScHARR), Items 4 to 4.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Present for all items

Claire Harrison, Professor of myeloproliferative neoplasms and clinical director, clinical expert, nominated by Novartis & MPN Voice, Items 1 to 3.1.3

Mark Hill, Patient expert, nominated by MPN Voice, Items 1 to 3.1.3

Charlotte Martin, patient expert, nominated by Leukaemia Care, Items 1 to 3.1.3

Tim Somervaille, Professor of Haematological Oncology, clinical expert, nominated by Novartis, Items 1 to 3.1.3

## Minutes

### Introduction to the meeting

* 1. The chair Dr Stephen Smith welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from Dr Megan John and Christopher Herring

### News and announcements

* 1. Committee welcomed two new members Andy Fox and Elliott Dash.

### Appraisal of ruxolitinib for treating polycythaemia vera - review of TA356 [ID5106]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Novartis.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11079/documents).

* + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Giles Monnickendam, Ivan Koychev, and Carole Pitkeathley
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta11079>

### Appraisal of cabozantinib for previously treated differentiated thyroid cancer unsuitable for or refractory to radioactive iodine [ID4046]

* 1. Part 1 – Open session
     1. The chair Dr Stephen Smith welcomed the NHS England expert, external assessment group representatives, members of the public and company representatives from Ipsen.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.

Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10932/documents).

* + 1. The Chair led a discussion of the consultation comments presented to the committee.
  1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10932>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Wednesday 14 June